From June 2018-May 2019, the Surveillance for Antineoplastic Exposures (SurFACEs) study monitored potential for inadvertent exposure to 11 different drugs on 20 different surfaces in 9 different hospitals in Alberta and Minnesota.
Research Project staff conducted a walk-through at each centre that followed the “path” of ADs in the facility from their receipt to their disposal. Surfaces for sampling were prioritized based upon what we already knew from other studies, from guidelines such as <USP 800>, and from discussion with staff at each centre. “High-touch” areas (handles, keypads, counters) were prioritized and care was taken to select surfaces that would be comparable between centres. During the walk-through, pictures were taken of each surface at each centre to create a reference document. The final list of surfaces selected were:
| Pharmacy | Clinic |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|